Melbourne patient was diagnosed with a rare blood-clotting disorder

It comes after several countries in Europe suspended the rollout of the AstraZeneca jab after some cases of blood-clotting following the vaccine were detected there.

What happened with the Australian case?

The 44-year-old Victorian man at the centre of the case received the AstraZeneca vaccine on March 22.

Almost a fortnight later, the man was then admitted to the Box Hill Hospital in Melbourne with serious thrombosis and a low platelet count.

Following Friday’s news of the man’s hospitalisation, the Therapeutic Goods Administration, and the government’s vaccine advisory group convened urgent meetings and launched an investigation.

While deputy chief medical officer Michael Kidd said a definitive connection had not been established between the case of thrombosis or blood-clotting and the vaccine, he said it was likely the man’s condition was linked to the vaccine.

What does this mean for the COVID vaccine?

Unlike other countries, which have come under fire from medical experts for suspending the rollout of the AstraZeneca vaccine following cases of blood-clotting, Australia’s rollout is proceeding as normal.

That’s despite the national rollout coming under fire for being too slow and missing the federal government’s March deadline of having more than 4 million vaccines administered.

So far, almost 900,000 doses of the vaccine have been given to Australians who are part of either phase 1a or 1b of the rollout. More than 400,000 of them have been the AstraZeneca vaccine.

Health Minister Greg Hunt said the AstraZeneca vaccine was still safe to use and had undergone rigorous testing before being approved for use.

Professor Kidd said no changes to the vaccine rollout were required while the TGA and the Australian Technical Advisory Group on Immunisation were carrying out investigations into the blood-clotting incidents.

“The risk of serious side effects remain very low,” he said. “We have not been advised at this time by ATAGI or the TGA to pause the rollout of the AstraZeneca vaccine in Australia. We continue to follow the medical advice of our national experts.”

What advice around the vaccine has changed?

While health experts have said the benefits of receiving the COVID-19 vaccine far outweigh potential side effects, the government’s vaccine advisory group advised people who had received the vaccine to be aware of some symptoms.

“Consumers should be particularly alert to severe, persistent headaches that are different to their ‘usual’ pattern and do not settle with paracetamol or other painkillers,” the group said in a statement.

“If these symptoms occur, consumers should seek medical advice as soon as possible.”

Side effects such as fever, sore muscles, tiredness and headaches are expected following the vaccine. The advisory group said they usually started within 24 hours of the vaccination and lasted for one to two days.

Healthcare workers have been advised to look out for symptoms of potential rare blood-clotting conditions in patients who received the vaccine.

The advisory group said in late March, following reports of clotting incidents in Europe, that vaccines should be deferred for people who had a history of rare clotting conditions. However, the group said the advice was only a precautionary measure.